Glenmark Pharmaceuticals, a global pharmaceutical company based in India, said it has signed an exclusive agreement with a South Korean company to sell six eye-related generic drugs in the US market.
The total U.S. brand sales for the six products was approximately $1.7 billion for calendar year 2017.
Glenmark said it expects to file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 to seek approval for selling the drugs in the US.
The agreement has been signed with Sam Chun Dang Pharm. Co of South Korea, which will be in charge of development and manufacturing.
“The agreement for these ophthalmic products is aligned with our strategy to strengthen our focus on complex generic formulations,” said Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals.
“Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio.”
The Sam Chun Dang Pharm. Co. Ltd. was established in 1943 and is based in Seoul, South Korea.
It offers ophthalmic solutions, solid orals, nasal solutions and ampules for a wide range of therapeutic classes.
It exports its products to Asia, the Middle East, North America, and throughout Latin America.
